CN117769419A - 用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉 - Google Patents

用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉 Download PDF

Info

Publication number
CN117769419A
CN117769419A CN202280040639.5A CN202280040639A CN117769419A CN 117769419 A CN117769419 A CN 117769419A CN 202280040639 A CN202280040639 A CN 202280040639A CN 117769419 A CN117769419 A CN 117769419A
Authority
CN
China
Prior art keywords
composition
use according
nitroquinoline
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280040639.5A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of CN117769419A publication Critical patent/CN117769419A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280040639.5A 2021-06-09 2022-06-09 用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉 Pending CN117769419A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
GB2108224.3 2021-06-09
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Publications (1)

Publication Number Publication Date
CN117769419A true CN117769419A (zh) 2024-03-26

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280040639.5A Pending CN117769419A (zh) 2021-06-09 2022-06-09 用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉

Country Status (12)

Country Link
US (1) US20240261276A1 (https=)
EP (1) EP4351576A1 (https=)
JP (1) JP2024520690A (https=)
KR (1) KR20240024175A (https=)
CN (1) CN117769419A (https=)
AU (1) AU2022290019A1 (https=)
BR (1) BR112023025789A2 (https=)
CA (1) CA3221964A1 (https=)
GB (1) GB202108224D0 (https=)
IL (1) IL309177A (https=)
MX (1) MX2023014530A (https=)
WO (1) WO2022258972A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039822C (en) * 2016-10-14 2026-02-17 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same

Also Published As

Publication number Publication date
GB202108224D0 (en) 2021-07-21
CA3221964A1 (en) 2022-12-15
EP4351576A1 (en) 2024-04-17
AU2022290019A1 (en) 2023-12-14
MX2023014530A (es) 2024-04-10
WO2022258972A1 (en) 2022-12-15
JP2024520690A (ja) 2024-05-24
BR112023025789A2 (pt) 2024-02-27
KR20240024175A (ko) 2024-02-23
US20240261276A1 (en) 2024-08-08
IL309177A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
Huang et al. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment
Zullo et al. Long-term effectiveness of presacral neurectomy for the treatment of severe dysmenorrhea due to endometriosis
Zhang et al. STING mediates neuroinflammatory response by activating NLRP3‐related pyroptosis in severe traumatic brain injury
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
JP6046702B2 (ja) 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤
Gisondi et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events
CN103533930A (zh) 用于治疗神经性疼痛的大麻素类化合物
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
CN117769419A (zh) 用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉
Cabrera et al. Lithium protects against glucocorticoid induced neural progenitor cell apoptosis in the developing cerebellum
US20160213669A1 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
JP2024540439A (ja) 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン
CN121197400A (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
KR20180035739A (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
US20230255943A1 (en) Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
US20160000804A1 (en) Inhibitors of na(v) 1.9 channel activity and uses thereof for treating pain
JP2019516696A (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
US20180071280A1 (en) Modulators of cell death processes
Hua et al. Gallic Acid Alleviates Cerebral Ischemia–reperfusion Injury in Mice by Mediating Microglial Polarization Through the NLRP3/mTOR Axis
CN120322233A (zh) 用于在恶性周围神经鞘瘤的治疗或预防中使用的硝羟喹啉
CN1911260A (zh) 蒲公英中酚酸类有效部位抑制妇科盆腔炎症的用途
El-Dwairi et al. Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles
CA3235075A1 (en) Methods of treating head and neck cancers with hemp extract
HK40050331A (zh) 用於治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination